431 completed, 87 terminated, 79 recruiting, 67 unknown. 747 Phase 2, 97 Phase 1, 63 Phase 3.
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| An Open-label Long-term Safety Study of Buntanetap in Participants With AD buntanetap/posiphen - Alzheimer's Dementia (AD) | Phase 2 / Phase 3 | Not yet recruiting | Annovis Bio Inc. | 400 | 2026-11-21 | 2026-11-12 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-18 | 2026-11-13 |
| Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease RO7568282, Placebo - Alzheimer's Disease | Phase 2 | Recruiting | Hoffmann-La Roche | 450 | 2026-11-15 | 2026-11-06 |
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease Empagliflozin, Insulin, Insulin Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Wake Forest University Health Sciences | 30 | 2026-11-01 | 2026-09-30 |
| A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg - Alzheimer Disease | Phase 2 | Not yet recruiting | Vigonvita Life Sciences | 200 | 2026-11-01 | 2026-10-29 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease RB-ADSC, Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Regeneration Biomedical, Inc. | 115 | 2026-10-01 | 2026-08-26 |
| Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor NBI-1117567, Placebo - Alzheimer's Disease | Phase 2 | Not yet recruiting | Neurocrine Biosciences | 135 | 2026-10-01 | 2026-09-22 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Flutemetamol F 18 Injection Formulation Comparison GE-287, Vizamyl - Cognitive Dysfunction | Phase 2 | Recruiting | GE Healthcare | 20 | 2026-09-30 | 2026-11-05 |
| Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease Obicetrapib 10 mg, Matching placebo tablets - Preclinical Alzheimer's Disease | Phase 2 | Recruiting | NewAmsterdam Pharma | 400 | 2026-09-01 | 2026-09-28 |
| 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients 2-hydroxybenzylamine acetate, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 / Phase 2 | Not yet recruiting | MTI Biotech Inc | 48 | 2026-09-01 | 2026-09-24 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-11-06 |
| N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease Nicotinamide Riboside (NR), Palacebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Haukeland University Hospital | 270 | 2026-08-26 | 2026-08-20 |
| Alzheimer's Disease Research Center (ADRC) PET Component Study 18F-MK6240, 18F-Florbetaben (FBB) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Patrick Lao | 120 | 2026-08-06 | 2026-08-11 |
Showing 20 of 747. Sign in to see all of them.
Alzheimer Disease (713) · Dementia (146) · Cognitive Dysfunction (145) · Neurodegenerative Diseases (33) · Supranuclear Palsy, Progressive (31) · Central Nervous System Diseases (27) · Brain Diseases (26) · Memory Disorders (22) · Nervous System Diseases (20) · Mental Disorders (18) · Plaque, Amyloid (17) · Inflammation (16) · Psychomotor Agitation (16) · Neurocognitive Disorders (14)
Nervous System Diseases (727) · Brain Diseases (720) · Central Nervous System Diseases (719) · Neurodegenerative Diseases (714) · Neurocognitive Disorders (706) · Mental Disorders (702) · Dementia (574) · Cognition Disorders (140) · Pathological Conditions, Signs and Symptoms (133) · Neurologic Manifestations (93) · Signs and Symptoms (91) · Neurobehavioral Manifestations (58) · Basal Ganglia Diseases (46) · Movement Disorders (45)
Donepezil (32) · florbetapir (14) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (10) · Saline Solution (10) · Sodium Chloride (9) · vanutide cridificar (9) · Insulin (7) · saponin QA-21V1 (7) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (6) · Levetiracetam (6) · Magnetic Resonance Spectroscopy (6) · 3-benzenesulfonyl-8-piperazin-1-ylquinoline (5) · AADvac1 (5) · ABT-126 (5) · Memantine (5)
Pfizer (22) · Eli Lilly and Company (15) · Avid Radiopharmaceuticals (13) · Chang Gung Memorial Hospital (12) · GlaxoSmithKline (11) · Merck Sharp & Dohme LLC (9) · University of Wisconsin, Madison (8) · AbbVie (7) · AbbVie (prior sponsor, Abbott) (7) · Boehringer Ingelheim (7) · Columbia University (7) · Hoffmann-La Roche (7) · Novartis Pharmaceuticals (7) · Sanofi (7) · Washington University School of Medicine (7)
United States (485) · Canada (98) · United Kingdom (83) · Spain (82) · France (79) · Germany (78) · Australia (66) · Italy (51) · Netherlands (45) · Japan (41) · South Korea (40) · Poland (38) · Sweden (34) · China (27) · Belgium (24)
Suzanne Craft, PhD (8) · Adam Boxer, MD, PhD (5) · Laura Gault, MD (5) · Bruno Kajiyama, MS (4)
PMID 25918556, PMID 33974419, PMID 39800465, PMID 40603145, PMID 33189083, PMID 34532852, PMID 25669746, PMID 25731629, PMID 26967206, PMID 26967214, PMID 27494299, PMID 27756421, PMID 27871675, PMID 29854923, PMID 30558645, PMID 30755255, PMID 31353964, PMID 31710528, PMID 31969177, PMID 32107748, PMID 32410694, PMID 33646153, PMID 33973646, PMID 34366147, PMID 34521461, PMID 34570177, PMID 34687726, PMID 36627206, PMID 36934371, PMID 36946448, PMID 38599894, PMID 38825840, PMID 39166791, PMID 39350369, PMID 39513754, PMID 39974075, PMID 40009460, PMID 40120616, PMID 40368603, PMID 40667684, PMID 41220869, PMID 41804324, PMID 42063312, PMID 42393277, PMID 12783912, PMID 15883262, PMID 17068314, PMID 17951067, PMID 18204357, PMID 18580589
2009 (11), 2023 (9), 2016 (8), 2014 (7), U01AG059798 (5), 2015 (4), 2018 (4), R01AG046179 (4), U01AG042791 (4), 2017 (3), 2025 (3), K23AG052633 (3), R01AG053267 (3), R01AG085029 (3), R56AG053267 (3)